Scagliotti, JCO 02; Souquet, Annals 02; Gebbia, Lung Cancer 03 ; Martoni, .

Pemetrexed. 500 mg/m². D 1. ▪ Cisplatin. 75 mg/m². D 1. ▪ Adenocarcinoma. +

9.4. 10.8. 0.05. NSCLC general 8.6. 9.2. 0.586. CIS/PEM vs CIS/GEM in 1st- LINE

Pirker OKP2010. Cisplatin/Pemetrexed versus. Cisplatin/Gemcitabine. Scagliotti

Mar 25, 2011 . 11. Overall Survival in Patients with. Nonsquamous Histology. Scagliotti. JCO.

Jul 20, 2008 . DOI: 10.1200/JCO.2007.15.0375 . Giorgio Vittorio Scagliotti, Purvish Parikh,

Differential effect of pemetrexed in non-squamous vs squamous cell carcinoma

Scagliotti GV, Novello S. Pemetrexed and its emerging role in the treatment of

Squamous Ca. Large cell Ca. NSCLC, NOS. Scagliotti G, et al: JCO 26:3543-51 .

Hematology-Oncology. Ann Arbor VA Medical Center and .

jco,. August 20, 2011. Increase of Ascites and Pleural Effusion Misleading .

Is there a single platinum-based doublet standard chemotherapy? ● Schiller,

1: Travis WD, Brambilla E, Van Schil P, Scagliotti GV, Huber RM, Sculier JP .

Mar 7, 2009 . Treatment based on therapy-predictive markers. • standard or ERCC1-

Jun 9, 2008 . JMDB OS curves by Histology JCO Scagliotti . JMDB OS curves by Histology JCO

Bone Marrow Transplantation . Cinta Pallares, Lesley Tye, Paulina Selaru,

Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it . Cis

L SCIEN. CES. Cis/Pem vs. Cis/Pem : Subgroup Analyses. U. N. IV. ER. STY O. F

Does Histology matter? Scagliotti GV, JCO 2008. Cisplatin (75mg/m2) d1. +

G. V. Scagliotti et al., JCO 26 (2008), 3543-51. Planned subset analysis!

ECOG1594: Schiller N Engl J Med 2004. 2. TAX 326: Fossella JCO 2003. 3.

2: Scagliotti GV, Novello S. The role of the insulin-like growth factor .

Clin Cancer Res 2009;15:7547-7552; Scagliotti GV, JCO 2008 CDDP + Alimta

Oct 13, 2009 . with the addition of vitamin supplementation. Median TTP: 4.7 months; median

Feb 16, 2009 . Disclosures: Giorgio Scagliotti: Honoraria: Eli Lilly and Company, . . Lung

Therapy with CPx showed clear activity and good tolerability in advanced

. May 2008 (Scagliotti JCO 2008) and May 2009 (ASCO 2009, 8045). Methods .

on JCO.org. Corresponding author: Giorgio Vittorio. Scagliotti, MD, University of

One study (N = 1725) tested cisplatin plus P versus cisplatin plus gemcitabine in

D. EP. T. O. F CLIN. IC. Giorgio V. Scagliotti. University of Torino .

Sep 25, 2009 . maintenance. Needs 12 weekly VitB12 IM. Predictable myelosupression. Very

Scagliotti GV JCO 26: 3543, 2008. * Purpose: cisplatin plus gemcitabine =

Nov 8, 2005 . Comparisons Head to Head : Scagliotti (JCO 2002) : GC 3W vs VC vs PCb 225 ;.

Giorgio V. Scagliotti, MD, PhD. University of . 3. 2. NA. * ECOG 1581 (

taxanes (paclitaxel or docetaxel) were prior standard treatment. • The purpose of

14%. Median time to progression: 4.7 months. Median survival: 10.7 months. 1

Vogelzang, N et al; JCO (2003); 21 (14): 2636 – 2644 (mesothelioma). Hughes, A

Scagliotti (JCO 2008). Non SCC. 10.3. 10.4. 5.1. 4.7. 28.2%*. NC. 0 %. 0 % .

Feb 1, 2011 . Scagliotti GV et al, JCO 2008 ; 6.) Pirker R. et al Lancet 2009 ; 7.) Sandler A et al,

Scagliotti et al., WCLC Korea 2007. R. A. N. D . Simon, JCO 2007, 25:2741 .

Dec 1, 2008 . DOI: 10.1200/JCO.2008.19.5560 . Giorgio V. Scagliotti .

NEJM. 2002;346;92-8. Sandler A ,et al. NEJM. 2006;355:2542-50. I-PASS. JMDB

Scagliotti's study showing identical results for the 'average patient' (Scagliotti,

Schiller NEJM 346:92, 2002; Fossela JCO 21:3016, 2003; Scagliotti JCO 26:

JCO 2006; 24, 18s part I of II. Abst 7210. Scagliotti GV, Novello S. The way

Pemetrexed 500 mg/m2 day 1. Vitamin B12, folate, and dexamethasone given in .

Hematology-Oncology. Ann Arbor VA Medical Center and .

. (Scagliotti JCO 2002) 10% *Scagliotti JCO 2008; Scagliotti Oncologist .

Mar 9, 2010. or With Sorafenib in Advanced Non-Small-Cell Lung Cancer -- Scagliotti et al

Mar 25, 2011 . N = 1700 Patients , Power 80%. B12, folate, and dexamethasone given in both

Sitemap